Compare Eli Lilly And Co (LLY) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Exxon Mobil Corporation — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Exxon Mobil Corporation trades at $168.95 (market cap $692.86B). The key difference: Eli Lilly And Co is the larger of the two by market cap, and Exxon Mobil Corporation pays the higher dividend (2.45%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Exxon Mobil Corporation for 99 Days on average.
| LLY | XOM | |
|---|---|---|
Market Cap | $1.04T | $692.86B |
Volume | 3,064,878 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $1.28K | $171.52 |
52-Week Low | $799.57 | $110.64 |
Typical Hold Time | 93 Days | 99 Days |
Enterprise Value | $1.09T | $724.64B |
Dividend Yield | 0.59% | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Exxon Mobil (XOM) trades at $164.06, down 0.26% on the day, with a bullish technical signal and strong support at $163. The company reported mixed Q2 2026 earnings, missing EPS estimates, but maintains solid profitability with a 9.07% net margin. Recent news highlights potential expansion into Venezuela's oil fields and ongoing growth in Guyana and Permian Basin assets. Cash flow from operations remains robust at $52.0 billion in 2025, though net cash flow was negative due to high capital expenditures.
XOM offers a stable dividend and growth potential from strategic investments, but faces risks from volatile oil prices and geopolitical exposure. Analyst consensus is a 'Hold' with a $169.45 price target, indicating modest upside. Revenue declines from 2022-2025 pose a concern, but projected 2026 growth to $361.1 billion may reverse the trend. The stock's valuation ratios, including a P/E of 21.69, are reasonable for the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
